{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:09:38Z","timestamp":1780549778410,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,6,15]],"date-time":"2014-06-15T00:00:00Z","timestamp":1402790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,6,15]],"date-time":"2014-06-15T00:00:00Z","timestamp":1402790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10637-014-0128-z","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T07:28:42Z","timestamp":1403162922000},"page":"1295-1300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity"],"prefix":"10.1007","volume":"32","author":[{"given":"Didem","family":"Tastekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makbule","family":"Tambas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,15]]},"reference":[{"key":"128_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"128_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","volume":"43","author":"AF Galimont-Collen","year":"2007","unstructured":"Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43:845\u2013851","journal-title":"Eur J Cancer"},{"key":"128_CR3","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol: Off J Am Soc Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"128_CR4","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","volume":"16","author":"S Segaert","year":"2005","unstructured":"Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol: Off J Eur Soc Med Oncol 16:1425\u20131433","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"128_CR5","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","volume":"26","author":"A Di Leo","year":"2008","unstructured":"Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 26:5544\u20135552","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","volume":"114","author":"ME Lacouture","year":"2009","unstructured":"Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, Gomez HL, Salazar VM, Byrne JA, Koch KM, Blackwell KL (2009) Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 114:485\u2013493","journal-title":"Breast Cancer Res Treat"},{"key":"128_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803\u2013812","journal-title":"Nat Rev Cancer"},{"key":"128_CR8","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","volume":"19","author":"M Hidalgo","year":"2001","unstructured":"Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol Off J Am Soc Clin Oncol 19:3267\u20133279","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169\u20131176","journal-title":"Br J Dermatol"},{"key":"128_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","volume":"147","author":"R Van Doorn","year":"2002","unstructured":"Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G (2002) Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147:598\u2013601","journal-title":"Br J Dermatol"},{"key":"128_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/JCO.20.1.110","volume":"20","author":"J Albanell","year":"2002","unstructured":"Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol Off J Am Soc Clin Oncol 20:110\u2013124","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/1535-7163.MCT-04-0238","volume":"4","author":"CD Woodworth","year":"2005","unstructured":"Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M (2005) Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 4:650\u2013658","journal-title":"Mol Cancer Ther"},{"key":"128_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491\u2013500","journal-title":"Lancet Oncol"},{"key":"128_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D\u2019Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"128_CR15","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology G (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol 23:8646\u20138654","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","volume":"90","author":"C Giro","year":"2009","unstructured":"Giro C, Berger B, Bolke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, Langendijk JA, Budach W (2009) High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol: J Eur Soc Ther Radiol Oncol 90:166\u2013171","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"key":"128_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 27:663\u2013671","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR18","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.2004.12.040","volume":"22","author":"HQ Xiong","year":"2004","unstructured":"Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol Off J Am Soc Clin Oncol 22:2610\u20132616","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"128_CR19","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.3816\/CLC.2006.s.008","volume":"8","author":"R Perez-Soler","year":"2006","unstructured":"Perez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 8(Suppl 1):S7\u2013S14","journal-title":"Clin Lung Cancer"},{"key":"128_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1470-2045(10)70278-3","volume":"12","author":"U Gatzemeier","year":"2011","unstructured":"Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O\u2019Byrne KJ, Pirker R (2011) First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 12:30\u201337","journal-title":"Lancet Oncol"},{"key":"128_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","volume":"8","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8:173\u2013181","journal-title":"Target Oncol"},{"key":"128_CR22","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1200\/JCO.2011.40.9243","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol Off J Am Soc Clin Oncol 30:2861\u20132868","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0367-326X(00)00277-X","volume":"72","author":"E Tuzlaci","year":"2001","unstructured":"Tuzlaci E, Aymaz PE (2001) Turkish folk medicinal plants, Part IV: Gonen (Balikesir). Fitoterapia 72:323\u2013343","journal-title":"Fitoterapia"},{"key":"128_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(01)01290-0","volume":"428","author":"EM Giner-Larza","year":"2001","unstructured":"Giner-Larza EM, Manez S, Recio MC, Giner RM, Prieto JM, Cerda-Nicolas M, Rios JL (2001) Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity. Eur J Pharmacol 428:137\u2013143","journal-title":"Eur J Pharmacol"},{"key":"128_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0367-326X(02)00318-0","volume":"74","author":"ME Duru","year":"2003","unstructured":"Duru ME, Cakir A, Kordali S, Zengin H, Harmandar M, Izumi S, Hirata T (2003) Chemical composition and antifungal properties of essential oils of three Pistacia species. Fitoterapia 74:170\u2013176","journal-title":"Fitoterapia"},{"key":"128_CR26","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1200\/JCO.2007.11.7275","volume":"25","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Wenzel L, Shaw E, Cella D (2007) Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol Off J Am Soc Clin Oncol 25:5058\u20135062","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA, Group MSTS (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer: Off J Multinatl Assoc Support Care Cancer"},{"key":"128_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ijc.27654","volume":"132","author":"S Stintzing","year":"2013","unstructured":"Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer J Int Cancer 132:236\u2013245","journal-title":"Int J Cancer J Int Cancer"},{"key":"128_CR29","first-page":"546","volume-title":"Flora of Turkey and the East Aegean Islands","author":"PH Davis","year":"1967","unstructured":"Davis PH (1967) Flora of Turkey and the East Aegean Islands, vol 2. Edinburgh at the University Press, Edinburgh, pp 546\u2013547"},{"key":"128_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1179\/joc.2001.13.6.611","volume":"13","author":"P Marone","year":"2001","unstructured":"Marone P, Bono L, Leone E, Bona S, Carretto E, Perversi L (2001) Bactericidal activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J Chemother 13:611\u2013614","journal-title":"J Chemother"},{"key":"128_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fitote.2004.09.021","volume":"76","author":"B Kivcak","year":"2005","unstructured":"Kivcak B, Akay S (2005) Quantitative determination of alpha-tocopherol in Pistacia lentiscus, Pistacia lentiscus var. chia, and Pistacia terebinthus by TLC-densitometry and colorimetry. Fitoterapia 76:62\u201366","journal-title":"Fitoterapia"},{"key":"128_CR32","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol: Off J Am Soc Clin Oncol 25:5390\u20135396","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"128_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","volume":"61","author":"A Scope","year":"2009","unstructured":"Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61:614\u2013620","journal-title":"J Am Acad Dermatol"},{"key":"128_CR34","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1634\/theoncologist.2010-0082","volume":"15","author":"A Jatoi","year":"2010","unstructured":"Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL (2010) Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 15:1016\u20131022","journal-title":"Oncologist"},{"key":"128_CR35","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/cncr.23621","volume":"113","author":"A Jatoi","year":"2008","unstructured":"Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847\u2013853","journal-title":"Cancer"},{"key":"128_CR36","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 28:1351\u20131357","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"128_CR37","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00432-013-1483-4","volume":"139","author":"TC Wehler","year":"2013","unstructured":"Wehler TC, Graf C, Mohler M, Herzog J, Berger MR, Gockel I, Lang H, Theobald M, Galle PR, Schimanski CC (2013) Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol 139:1667\u20131672","journal-title":"J Cancer Res Clin Oncol"},{"key":"128_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.suponc.2010.09.003","volume":"8","author":"SF Wong","year":"2010","unstructured":"Wong SF, Lindgren A, Mummaneni M, Byun T, Vasko C, Arenos R, Alexson E, Osann K (2010) A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors. J Support Oncol 8:202\u2013208","journal-title":"J Support Oncol"},{"key":"128_CR39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1684\/ejd.2010.0806","volume":"20","author":"K Katzer","year":"2010","unstructured":"Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A (2010) Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - a report of 29 patients. Eur J Dermatol 20:82\u201384","journal-title":"Eur J Dermatol"},{"key":"128_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2478\/v10019-010-0036-6","volume":"44","author":"J Ocvirk","year":"2010","unstructured":"Ocvirk J (2010) Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream. Radiol Oncol 44:265\u2013266","journal-title":"Radiol Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0128-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0128-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0128-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0128-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:55:37Z","timestamp":1678510537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0128-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,15]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["128"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0128-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,15]]},"assertion":[{"value":"14 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}